Avanza Fonder AB Invests $157,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Avanza Fonder AB purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 16,652 shares of the biopharmaceutical company’s stock, valued at approximately $157,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. OLD Second National Bank of Aurora purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth about $26,000. Hazlett Burt & Watson Inc. grew its stake in shares of Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares during the last quarter. Blue Trust Inc. increased its position in Amicus Therapeutics by 1,705.4% during the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI bought a new stake in Amicus Therapeutics in the third quarter worth $32,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Amicus Therapeutics during the third quarter valued at $55,000.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. This represents a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders have sold 22,901 shares of company stock worth $259,863. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $9.41 on Monday. The company has a 50-day moving average price of $9.70 and a 200-day moving average price of $10.53. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $2.81 billion, a P/E ratio of -27.68, a PEG ratio of 1.25 and a beta of 0.62. Amicus Therapeutics, Inc. has a 52 week low of $8.78 and a 52 week high of $14.03.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on FOLD. Bank of America raised their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Morgan Stanley restated an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. JPMorgan Chase & Co. upped their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.88.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.